Parsons And Battelle Deliver Industry-Leading PFAS Investigation Capabilities
Parsons Corporation (NYSE: PSN) announced a collaboration with Battelle Memorial Institute to enhance their PFAS investigation capabilities. This partnership aims to utilize Parsons’ innovative PFAS investigation methods alongside Battelle’s advanced analytical tools to offer cost-effective and efficient solutions for clients facing PFAS issues. The urgency is underscored by a $10 billion funding allocation from the Infrastructure Investment and Jobs Act to investigate PFAS contamination, highlighting the growing significance of this environmental challenge.
- Strategic partnership with Battelle to enhance PFAS investigation capabilities.
- Access to $10 billion in funding from the Infrastructure Investment and Jobs Act to address PFAS issues.
- None.
CENTREVILLE, Va., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) announced today that the company has entered into a collaborative agreement with Battelle Memorial Institute (Battelle) to combine Parsons’ unique per- and polyfluoroalkyl substances (PFAS) investigation approach and tools with Battelle’s patented PFAS analytical and site investigation tools and technologies. The combined capabilities will deliver a unique and highly advanced approach to help clients quickly, efficiently, and cost effectively investigate potential PFAS impacts and understand PFAS liabilities.
PFAS is one of today’s most significant environmental issues, and is being addressed around the world at aviation, industrial, manufacturing, and wastewater treatment facilities. The bipartisan Infrastructure Investment and Jobs Act (IIJA) allocates
“We recognize there is no one-size-fits-all approach to PFAS investigation, and our approach is complementary with Battelle’s investigation technologies to produce extremely high quality data quickly and cost-efficiently,” said Joe Cudney, senior vice president, energy and environment, for Parsons. “Our combined capabilities will provide a powerful PFAS investigation market discriminator, mitigating risks and liabilities through innovation, insight, and advocacy.”
Parsons’ investigation approach utilizes rapid data production, real-time data interpretation, and three- dimensional model updates to actualize field-based decision making and bring more value to the investigation dataset. Battelle’s investigation technologies include source tracking for PFAS, rapid tests to determine PFAS presence, fate and transport modeling specifically designed for PFAS, passive PFAS sampling devices, and an optimized total oxidizable precursor assay.
To learn more about Parsons’ PFAS capabilities, visit Parsons.com/PFAS.
About Parsons:
Parsons (NYSE: PSN) is a leading disruptive technology provider in the global security, intelligence, and critical infrastructure markets, with capabilities across cybersecurity, missile defense, space, connected infrastructure, and smart cities. Please visit parsons.com, and follow us on LinkedIn and Facebook to learn how we’re making an impact.
Forward-Looking Statements
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on our current expectations, beliefs and assumptions, and are not guarantees of future performance. Forward-looking statements are inherently subject to uncertainties, risks, changes in circumstances, trends and factors that are difficult to predict, many of which are outside of our control. Accordingly, actual performance, results and events may vary materially from those indicated in the forward-looking statements, and you should not rely on the forward-looking statements as predictions of future performance, results or events. Numerous factors could cause actual future performance, results and events to differ materially from those indicated in the forward-looking statements, including, among others: any issue that compromises our relationships with the U.S. federal government or its agencies or other state, local or foreign governments or agencies; any issues that damage our professional reputation; changes in governmental priorities that shift expenditures away from agencies or programs that we support; our dependence on long-term government contracts, which are subject to the government’s budgetary approval process; the size of our addressable markets and the amount of government spending on private contractors; failure by us or our employees to obtain and maintain necessary security clearances or certifications; failure to comply with numerous laws and regulations; changes in government procurement, contract or other practices or the adoption by governments of new laws, rules, regulations and programs in a manner adverse to us; the termination or nonrenewal of our government contracts, particularly our contracts with the U.S. federal government; our ability to compete effectively in the competitive bidding process and delays, contract terminations or cancellations caused by competitors’ protests of major contract awards received by us; our ability to generate revenue under certain of our contracts; any inability to attract, train or retain employees with the requisite skills, experience and security clearances; the loss of members of senior management or failure to develop new leaders; misconduct or other improper activities from our employees or subcontractors; our ability to realize the full value of our backlog and the timing of our receipt of revenue under contracts included in backlog; changes in the mix of our contracts and our ability to accurately estimate or otherwise recover expenses, time and resources for our contracts; changes in estimates used in recognizing revenue; internal system or service failures and security breaches; and inherent uncertainties and potential adverse developments in legal proceedings, including litigation, audits, reviews and investigations, which may result in materially adverse judgments, settlements or other unfavorable outcomes. These factors are not exhaustive and additional factors could adversely affect our business and financial performance. For a discussion of additional factors that could materially adversely affect our business and financial performance, see the factors included under the caption “Risk Factors” in our Registration Statement on Form S-1 and our other filings with the Securities and Exchange Commission. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. We assume no obligation to update any forward-looking statement made in this presentation that becomes untrue because of subsequent events, new information or otherwise, except to the extent we are required to do so in connection with our ongoing requirements under federal securities laws.
Media Contact:
Bernadette Miller
+1 980.253.9781
Bernadette.Miller@Parsons.com
Investor Relations Contact:
Dave Spille
+ 1 571.655.8264
Dave.Spille@parsons.com
FAQ
What recent collaboration did Parsons Corporation (PSN) announce?
How will the partnership with Battelle benefit Parsons (PSN)?
What is the significance of PFAS investigation funding for Parsons (PSN)?
What are PFAS, and why are they important for Parsons (PSN)?
